Navigation Links
Response Genetics Announces Publication of a Phase III Clinical,Trial Demonstrating That Low Levels of ERCC-1 Help to Predict,Likelihood of Response to Cisplatin-Based Therapy in Lung Cancer

- First prospective biomarker trial in non-small cell lung cancer -

LOS ANGELES, July 09, 2007 /PRNewswire-FirstCall/ -- Response Genetics, Inc. today announced that positive Phase III clinical data published in the July 1 issue of the Journal of Clinical Oncology suggests that low expression of the biomarker Excision-Repair Cross-Complementing 1 (ERCC-1) in patient biopsies with advanced non-small cell lung cancer (NSCLC) predicts for sensitivity to cisplatin-based chemotherapy. ERCC-1 is an enzyme involved in repair of DNA strand breaks such as those caused by cisplatin. The analysis of ERCC-1 levels in this study was conducted by Response Genetics using its RGI-1 technology. Data from previous studies published by the Company in Clinical Cancer Research 2002 and Annals of Oncology 2006 showing that ERCC-1 was associated with tumor sensitivity to cisplatin formed the basis for the present study. This is the first prospective study using a biomarker to predict chemotherapy response in lung cancer. These findings support the use of measurement of ERCC-1 for individualizing therapies for lung cancer patients.

The Phase III multicenter, randomized study was designed to determine the overall response rate (complete plus partial responses) of patients with stage IIIb or IV NSCLC to cisplatin-based therapy by determining levels of the biomarker ERCC-1 mRNA in their paraffin-embedded tissue biopsy before administering treatment. Patients were prospectively assigned treatment to a cisplatin or non-cisplatin-based chemotherapy depending on whether the ERCC-1 gene expression in their tumor sample was above or below a specific threshold. Patients were assigned to one of two arms in this trial. The control arm consisted of all patients receiving cisplatin-based therapy. Patients in the "genotypic" arm were separated by levels of ERCC-1. Cisplatin-based therapy (docetaxel/cisplatin) was assigned to patients with low
'"/>




Page: 1 2 3 4

Related medicine technology :

1. TMC125 Showed Significant Virologic Response at Week 24 in Treatment-Experienced HIV Patients With NNRTI Resistance in Phase 3 Trials
2. Trexima (Sumatriptan/Naproxen Sodium) Demonstrated Migraine-Free Response Across Multiple Attacks
3. Cervarix, the GSK Cervical Cancer Candidate Vaccine, Provides Sustained Immune Response in 100 Percent of Women up to 55 Years of Age
4. Data Demonstrated Metastatic Melanoma Response to Investigational Immunotherapy Ipilimumab
5. Ontak (denileukin diftitox) Achieves 49.1% Overall Response Rate in Phase III Trial of Cutaneous T-Cell Lymphoma (CTCL)
6. Introgen Reports Updated Phase 2 Advexin Data Correlating Improved Survival, Tumor Responses and Predictive p53 Biomarker
7. Dasatinib Shows High Early Response Rate as First Treatment for Chronic Myelogenous Leukemia, M. D. Anderson Researchers Report
8. Inovio Biomedicals DNA Delivery Technology Shows Safety and Enhances Gene Expression & Tumor Responses in Interim Melanoma Clinical Study Results
9. CEL-SCIS CEL-1000 Shown to Significantly Enhance Immune Response Against Avian Flu Antigen in Animals
10. VGX Pharmaceuticals Novel HIV and Pandemic Influenza DNA Vaccine Candidates Trigger Robust Immune Responses and Protection in Pre-Clinical Models
11. Vicals Vaxfectin Adjuvant With Needle-free Delivery Enhances DNA Vaccine Performance; Yields Antibody Responses Comparable to Electroporation Without Tolerability Issues
Post Your Comments:
(Date:9/19/2014)... , Sept. 19, 2014  Over 200 runners participated ... to Benefit the Radiation Oncology Institute (ROI), hosted by ... Golden Gate Park in San Francisco.  ... , CEO of Radiation Business Solutions, "but at ... raised over $70,000 for the ROI this year. This ...
(Date:9/19/2014)...  CytRx Corporation (Nasdaq: CYTR ), a ... announced that David J. Haen , Vice President, ... the Biotech Industry Conference on Friday, September 26 th ... place at the Millennium Broadway Hotel in ... and archived webcast of the presentation will be available ...
(Date:9/19/2014)... VIENNA, Austria , September 19, 2014 ... glucose control persist for many years in people with ... to produce major long term benefits for the kidneys." ... control in patients with type 2 diabetes leads to ... to usual care. The global study has ...
Breaking Medicine Technology:Fifth Annual 5K Run for the Future to Benefit the Radiation Oncology Institute Breaks Attendance, Donation Records 2Fifth Annual 5K Run for the Future to Benefit the Radiation Oncology Institute Breaks Attendance, Donation Records 3CytRx to Present at BioCentury's 2014 NewsMakers in the Biotech Industry Conference 2CytRx to Present at BioCentury's 2014 NewsMakers in the Biotech Industry Conference 3ADVANCE-ON Post-trial Observational Study: Blood Pressure Arm and Glucose Arm Results 2ADVANCE-ON Post-trial Observational Study: Blood Pressure Arm and Glucose Arm Results 3
... Hope for Treatment of,Children, WHITE PLAINS, N.Y., Feb. ... rare craniofacial birth defect in,mice and holds promise to ... funded in part by the March of Dimes., ... Nature Medicine,demonstrates the potential for translating basic research into ...
... BEIJING, Feb. 6 /Xinhua-PRNewswire-FirstCall/ -- Lotus Pharmaceuticals,Inc. ... "Company"), a,pharmaceutical company in the People,s Republic ... achieved significant milestones in the development of,isosorbide ... drug,for the prevention and treatment of angina., ...
Cached Medicine Technology:Molecular Therapy Succeeds in Preventing Craniofacial Birth Defect in Mice 2Lotus Pharmaceuticals, Inc. Achieves Significant Milestones in the Development of Isosorbide Mononitrate Sustained Release Tablets 2Lotus Pharmaceuticals, Inc. Achieves Significant Milestones in the Development of Isosorbide Mononitrate Sustained Release Tablets 3
(Date:9/21/2014)... the physical activity benefits of active play, a new ... children, playing has no goal it is an ... alone or with friends, and it represents "an opportunity ... boredom, sadness, fear, or loneliness." "By focusing on the ... aspects of play that are beneficial to young people,s ...
(Date:9/21/2014)... BC (PRWEB) September 21, 2014 Burnaby ... educational information to clients in order to help them ... sessions held at the clinic that will help clients ... they can also take active participation in the healing ... and posture, clients will be able to facilitate the ...
(Date:9/21/2014)... 2014 Over the past five years, ... inundate the market, thereby cutting into revenue growth for ... to data from Industry Canada, the loss of patent ... and $2.5 billion in 2010 and 2012, respectively. “In ... which has hampered revenue growth, many pharmaceutical manufacturers have ...
(Date:9/21/2014)... (PRWEB) September 21, 2014 The ... BHWG) will host a statewide symposium ( tinyurl.com/ILBHC14 ... Veterans, and their Families. Sponsored by the VNA ... Lottery Cash Grant, and Health & Disability Advocates, ... at the Hilton Hotel in Springfield, IL. ...
(Date:9/21/2014)... SUNDAY, Sept. 21, 2014 (HealthDay News) -- Young women ... and know which foods they should eat. But they ... nutritional choices, according to a new study. ... the University of Illinois,s Peer Education Exercising and Eating ... what would they choose to eat if they were ...
Breaking Medicine News(10 mins):Health News:Narrow focus on physical activity could be ruining kids' playtime 2Health News:Burnaby Physiotherapists Now Provide Educational Information for Preventative Care 2Health News:Brand Name Pharmaceutical Manufacturing in Canada Industry Market Research Report Now Available from IBISWorld 2Health News:Brand Name Pharmaceutical Manufacturing in Canada Industry Market Research Report Now Available from IBISWorld 3Health News:Enhancing Clinical Competence to Serve Veterans, a Statewide Symposium 2Health News:Enhancing Clinical Competence to Serve Veterans, a Statewide Symposium 3Health News: College Women Can Use Food Strategies, Study Finds 2
... Oct. 8 Boston Scientific,(NYSE: BSX ) announced ... third quarter results, which it plans to report on ... a $250 million milestone,payment from Abbott Laboratories (NYSE: ... Guidant,s vascular intervention and endovascular,solutions businesses. As a result, ...
... Weight Watchers,International, Inc. (NYSE: WTW ) ... serve as its President, North America, effective November,3, ... product,operations and general management experience, will oversee the ... products,publishing and licensing businesses and will be reporting ...
... sometimes goes awry has been implicated in breast cancer. ... of the Notch pathway may contribute to breast cancer. ... Drs Jane Visvader and Geoff Lindeman from the Victorian ... Notch genes in regulating breast development and function. ...
... Bulletin Board:,VYTC) today announced that effective October 7, ... an independent scientific consultant to Vyta Corp.,Dr. Sorgente ... at,BIOAGRA, LLC, a joint venture, equally owned by ... 2008, Vyta Corp announced its filing of,foreclosure litigation ...
... 8 Mass casualty incidents --,such as terrorist ... or hurricanes -- raise the life-and-death reality that,existing ... for all who,need it. One of the most ... requiring respiratory support., Disaster specialists and health ...
... Tampa, FL (Oct. 8, 2008) Women, the elderly, ... are all less likely to receive same-day coronary angioplasty ... South Florida researchers found. Their study was published this ... Cardiology . , Angioplasty, also known as percutaneous ...
Cached Medicine News:Health News:Boston Scientific Announces Third Quarter Adjustments 2Health News:Boston Scientific Announces Third Quarter Adjustments 3Health News:Boston Scientific Announces Third Quarter Adjustments 4Health News:Boston Scientific Announces Third Quarter Adjustments 5Health News:Weight Watchers Names Steven C. McCormick as President, North America 2Health News:Weight Watchers Names Steven C. McCormick as President, North America 3Health News:Vyta Corp Announces Engagement of Dr. Nino Sorgente as Independent Consultant 2Health News:Missouri Firm's New Ventilator Design Addresses Serious Homeland Security Issue 2Health News:Missouri Firm's New Ventilator Design Addresses Serious Homeland Security Issue 3Health News:Florida study finds barriers to angioplasty for life-threatening heart attacks 2Health News:Florida study finds barriers to angioplasty for life-threatening heart attacks 3
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: